drugset
drugset / Trial / NCT05836805

A Study of the Absorption, Metabolism and Excretion of [14C]XZP-3621 in Human

NCT05836805 ↗

Phase 1 Unknown 6 enrolled Xuanzhu Biopharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This non-randomized, single group, open-label study will investigate the mass balance, routes of elimination, pharmacokinetics, metabolism, safety and tolerability of a single oral dose of \[14C\]XZP-3621 in healthy volunteers.

Timeline

Start
2023-05
Primary completion
2023-08
Completion
2023-09

Drugs

EvaluationDrugModalityDoseRoute
Subject XZP-3621 Unknown 400 mg Oral

Indications

No indication recorded.